Reconsidering Efficacy and Safety: A Critical Appraisal of Repurposing Anti-inflammatory Targeted Drugs in Darier disease

Authors

  • Estelle Burle Department of Dermatology and Allergology, Toulouse University Hospital, Toulouse, France https://orcid.org/0009-0005-1641-3242
  • Juliette Mazereeuw-Hautier Department of Dermatology and Allergology, Toulouse University Hospital, Toulouse, France; Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Toulouse, Toulouse, France
  • Maella Severino-Freire Department of Dermatology and Allergology, Toulouse University Hospital, Toulouse, France; Reference Centre for Rare Skin Diseases, Dermatology Department, CHU Toulouse, Toulouse, France

DOI:

https://doi.org/10.2340/actadv.v106.adv-2026-0322

Keywords:

darier, Interleukin-17, Interleukin-23, JAK inhibitors, genodermatosis, biologic agents

Downloads

Download data is not yet available.

References

Sakuntabhai A, Ruiz-Perez V, Carter S, Jacobsen N, Burge S, Monk S, et al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet 1999; 21: 271–277. DOI: https://doi.org/10.1038/6784

Burge SM, Wilkinson JD. Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol 1992; 27: 40–50. DOI: https://doi.org/10.1016/0190-9622(92)70154-8

Ettinger M, Kimeswenger S, Deli I, Traxler J, Altrichter S, Noack P, et al. Darier disease: current insights and challenges in pathogenesis and management. J Eur Acad Dermatol Venereol 2025; 39: 942–951. DOI: https://doi.org/10.1111/jdv.20448

Busto Leis JM, Negre GS, Mayor Ibarguren AP, Pinto PH. Response of darier disease following treatment with baricitinib. JAMA Dermatol 2022; 158: 699–701. DOI: https://doi.org/10.1001/jamadermatol.2022.1021

Bianco M, Di Giulio S, Ibba L, Narcisi A, Costanzo A, Gargiulo L. Clearance of Darier disease lesions in a patient with concomitant atopic dermatitis treated with abrocitinib. J Eur Acad Dermatol Venereol 2025; 39: e417–e419. DOI: https://doi.org/10.1111/jdv.20399

Giorgio CM, Di Brizzi EV, Licata G, Fiorentino C, Argenziano G, Balato A. Brodalumab for darier disease: a case series highlighting il-17 inhibition as a potential treatment. Int J Dermatol 2025; 64: 1720–1722. DOI: https://doi.org/10.1111/ijd.17751

Alzahrani N, Grossman-Kranseler J, Swali R, Fiumara K, Zancanaro P, Tyring S, et al. Hailey-Hailey disease treated with dupilumab: a case series. Br J Dermatol 2021; 185: 680–682. DOI: https://doi.org/10.1111/bjd.20475

Soto-García D, Dávila-Seijo P, González-Moure C, Pampín A, Zulaica A, Allegue F, et al. Trametinib as a promising therapy for Darier disease: case report. Br J Dermatol 2025; 193: 339–341. DOI: https://doi.org/10.1093/bjd/ljaf160

Downloads

Published

2026-04-22

How to Cite

Burle, E., Mazereeuw-Hautier, J., & Severino-Freire, M. (2026). Reconsidering Efficacy and Safety: A Critical Appraisal of Repurposing Anti-inflammatory Targeted Drugs in Darier disease. Acta Dermato-Venereologica, 106, adv–2026. https://doi.org/10.2340/actadv.v106.adv-2026-0322

Issue

Vol. 106 (2026)

Section

Research letter

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC